In a GDSC query assessing I-BRD9 sensitivity across 958 cell lines, the cell lines susceptible to BRD9 inhibition were predominantly from hematological malignancies (89% compared to the expected 17%), notably including CLL (Fig. 6B, Supplementary Table 9) [39]. This evidence concerns the gene BRD9 and hematologic disorder.